BECTON DICKINSON & CO (BDX) Insider Transactions
Over the last 12 months, 26 BECTON DICKINSON & CO (BDX) insiders filed 91 SEC Form 4 transactions — $1.0M in open-market purchases ( 1 distinct buyers) and $4.5M in open-market sales. 0% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $1.0MOpen-market buys (1y)
- $4.5MOpen-market sells (1y)
- 26Distinct insiders
- 91Transactions filed
- 0%Under Rule 10b5-1 plan
- 2026-06-10Latest filing
Recent Form 4 Filings Most recent 50 of 91 (1-year window)
Each row is a single Form 4 filing event for BDX, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.
| Date | Insider | Title | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-06-10 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Sell | S | $166.6K | 1,100 | $151.48 |
| 2026-06-01 | Polen Thomas E Jr | Chairman, CEO and President | Exercise | M | $2.5M | 20,209 | $126.16 |
| 2026-06-01 | Polen Thomas E Jr | Chairman, CEO and President | Exercise | M | $0 | 20,209 | $0.00 |
| 2026-06-01 | Menziuso Peter | EVP and President, BDI | Grant | A | $0 | 14,258 | $0.00 |
| 2026-06-01 | Polen Thomas E Jr | Chairman, CEO and President | Sell | D | $2.5M | 17,445 | $146.15 |
| 2026-06-01 | Polen Thomas E Jr | Chairman, CEO and President | Sell | S | $404.5K | 2,764 | $146.35 |
| 2026-05-26 | Feld Michael | EVP, Chief Revenue Officer | Sell | S | $11.1K | 75 | $147.35 |
| 2026-05-08 | Huffines Robert Luther | — | Grant | A | $31.3K | 210 | $149.04 |
| 2026-05-08 | Byington Carrie L | — | Grant | A | $15.6K | 105 | $149.04 |
| 2026-05-07 | Roque Vitor | EVP & Chief Financial Officer | Grant | A | $0 | 1,721 | $0.00 |
| 2026-04-27 | Feld Michael | EVP, Chief Revenue Officer | Sell | S | $11.2K | 74 | $151.94 |
| 2026-04-06 | Neal Shana Carol | EVP and Chief People Officer | Other | F | $0 | 1,146 | $0.00 |
| 2026-03-26 | Feld Michael | EVP, Chief Revenue Officer | Sell | — | $11.8K | 75 | $156.83 |
| 2026-03-16 | Minnix Lanesha | EVP and General Counsel | Grant | — | $0 | 7,492 | $0.00 |
| 2026-03-02 | Roque Vitor | Interim CFO | Grant | — | $0 | 931 | $0.00 |
| 2026-03-02 | Spikner Pamela L. | SVP Controller & CAO | Grant | — | $0 | 931 | $0.00 |
| 2026-02-26 | Feld Michael | EVP, Chief Revenue Officer | Sell | — | $13.6K | 75 | $181.84 |
| 2026-02-18 | SCOTT BERTRAM L | — | Sell | — | $174.0K | 953 | $182.61 |
| 2026-02-04 | Huffines Robert Luther | — | Grant | — | $20.2K | 100 | $201.91 |
| 2026-02-04 | Byington Carrie L | — | Grant | — | $6.1K | 30 | $201.91 |
| 2026-02-04 | Jones Christopher Ian Montague | — | Grant | — | $54.9K | 272 | $201.91 |
| 2026-01-27 | Henderson Jeffrey William | — | Grant | — | $0 | 1,098 | $0.00 |
| 2026-01-27 | ECKERT R ANDREW | — | Grant | — | $0 | 1,098 | $0.00 |
| 2026-01-27 | Byington Carrie L | — | Grant | — | $0 | 1,098 | $0.00 |
| 2026-01-27 | HAYES GREGORY | — | Grant | — | $0 | 1,098 | $0.00 |
| 2026-01-27 | Brown William M | — | Grant | — | $0 | 1,098 | $0.00 |
| 2026-01-27 | Huffines Robert Luther | — | Grant | — | $0 | 1,098 | $0.00 |
| 2026-01-27 | Jones Christopher Ian Montague | — | Grant | — | $0 | 1,098 | $0.00 |
| 2026-01-27 | RING TIMOTHY M | — | Grant | — | $0 | 1,098 | $0.00 |
| 2026-01-27 | SCOTT BERTRAM L | — | Grant | — | $0 | 1,098 | $0.00 |
| 2026-01-27 | Waldstreicher Joanne | — | Grant | — | $0 | 1,098 | $0.00 |
| 2026-01-27 | Wright Jacqueline | — | Grant | — | $0 | 1,098 | $0.00 |
| 2026-01-26 | Feld Michael | EVP, CRO & Pres. Life Sciences | Sell | — | $15.2K | 75 | $202.73 |
| 2026-01-21 | Spikner Pamela L. | SVP Controller & CAO | Grant | — | $0 | 84 | $0.00 |
| 2026-01-15 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Grant | — | $512.8K | 3,054 | $167.91 |
| 2026-01-15 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Grant | — | $512.9K | 2,454 | $209.00 |
| 2026-01-15 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Grant | — | $0 | 3,054 | $0.00 |
| 2026-01-15 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Sell | — | $125.4K | 600 | $209.00 |
| 2026-01-15 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Sell | — | $208.6K | 1,010 | $206.54 |
| 2026-01-03 | Shan David | EVP and Chief ISC Officer | Grant | — | $0 | 44 | $0.00 |
| 2025-12-26 | Feld Michael | EVP, CRO & Pres. Life Sciences | Sell | — | $14.5K | 74 | $196.08 |
| 2025-12-17 | Garrison Michael David | EVP & Pres Med.Essntl&BioPharm | Sell | — | $123.3K | 629 | $196.03 |
| 2025-12-01 | Wright Jacqueline | — | Grant | — | $0 | 180 | $0.00 |
| 2025-12-01 | Huffines Robert Luther | — | Grant | — | $0 | 180 | $0.00 |
| 2025-12-01 | Feld Michael | EVP, CRO & Pres. Life Sciences | Sell | — | $14.5K | 75 | $193.36 |
| 2025-11-26 | Mocherla Pavan Kumar | EVP & President, Greater Asia | Grant | — | $0 | 2,208 | $0.00 |
| 2025-11-26 | Mocherla Pavan Kumar | EVP & President, Greater Asia | Grant | — | $0 | 708 | $0.00 |
| 2025-11-26 | Shan David | EVP and Chief ISC Officer | Grant | — | $0 | 3,504 | $0.00 |
| 2025-11-26 | Shan David | EVP and Chief ISC Officer | Grant | — | $0 | 1,025 | $0.00 |
| 2025-11-26 | Shan David | EVP and Chief ISC Officer | Grant | — | $0 | 134 | $0.00 |
Showing the most recent 50 of 91 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.
Top Insider Buyers of BDX By dollar volume, 1-year window
- HAYES GREGORY $1.0M
Methodology & FAQ
How We Track BDX Insider Transactions
Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.
What is an SEC Form 4 filing for BECTON DICKINSON & CO?
Form 4 is a transaction-level disclosure that corporate insiders — officers, directors, and beneficial owners of more than 10% of a registered class of equity securities — must file with the SEC within two business days of any change in their beneficial ownership of BECTON DICKINSON & CO (BDX) shares.
What is a Rule 10b5-1 trading plan?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.
How is "insider buying" different from a stock grant or option exercise?
An insider buy (SEC transaction code P) is an open-market purchase of BECTON DICKINSON & CO (BDX) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.
How recent is the data?
Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.